327-75-3

应用筛选条件

关键词:'327-75-3'

显示 1-5 共 5 条结果关于 "327-75-3" 范围论文

Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours.

Charlotta Ryk et al.

Cancer letters, 241(1), 142-149 (2005-12-14)

We studied the effects of polymorphisms in nine genes involved in DNA repair and detoxification on occurrence and type of p53 mutation in 327 bladder cancer patients. The included polymorphisms are XPC(Lys939Gln), XPD(Lys751Gln), XPG(Asp1104His), XRCC1(Arg3999Gln), XRCC3(Thr241Met), NBS1(Glu185Gln), cyclin D1(Pro241Pro), MTHFR(Ala222Val

The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.

S Garasto et al.

Annals of human genetics, 67(Pt 1), 54-62 (2003-01-31)

The genes coding for apolipoprotein A1 (APOA1), apolipoprotein C3 (APOC3) and apolipoprotein A4 (APOA4) are tandemly organised within a short region on chromosome 11q23-q24. Polymorphisms of these genes have been extensively investigated in lipoprotein disorders and cardiovascular diseases, but poorly

[Influence of gender on the potency and course of action of rocuronium bromide].

D Steinberg

Revista espanola de anestesiologia y reanimacion, 56(10), 604-611 (2010-02-16)

The correlation between gender and the potency of certain neuromuscular blockers, including rocuronium, has been investigated. However, the methods used have been inconsistent. This study aimed to look further at the role of gender in order to arrive at definitive

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Se Joon Woo et al.

JAMA ophthalmology, 139(1), 68-76 (2020-11-20)

Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. To demonstrate equivalence of efficacy, similar

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Gregory J Moran et al.

The Lancet. Infectious diseases, 14(8), 696-705 (2014-06-10)

New antibiotics are needed to treat infections caused by drug-resistant bacteria. Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against Gram-positive pathogens. We aimed to assess the efficacy and safety of intravenous to oral tedizolid for

1/1